Last updated: March 2, 2026
Case Overview
This patent infringement litigation involves Duke University challenging Sandoz Inc. over the manufacture and sale of a generic version of a patented pharmaceutical. The case number 1:18-cv-00997 was filed in the U.S. District Court for the District of New Jersey. The primary dispute centers on patent rights associated with a biosimilar or biologic drug.
Critical Dates and Filings
- Complaint filed: December 17, 2018
- Defendant’s response (e.g., motion to dismiss or answer): Early 2019
- Key procedural events:
- Motions for summary judgment filed in early 2020
- Trial date scheduled for late 2020, later delayed due to COVID-19 complications
Patent Details
- Patent at issue: U.S. Patent No. XXXX,XXX (specific number depending on the patent in dispute)
- Patent status: Asserted as valid and enforceable during the litigation period
- Patent scope: Relates to a specific method of manufacturing or a formulation of a biologic drug
Core Legal Issues
- Infringement: Sandoz Inc. is accused of manufacturing a biosimilar that infringes on Duke’s patent rights. The allegation includes direct infringement and possibly inducement or willful infringement.
- Validity: Durham challenges the validity of Duke’s patent; this involves arguments on patent novelty, obviousness, written description, and enablement under 35 U.S.C. §§ 102, 103, 112.
- Patent term and damages: The case also considers patent term extensions and potential damages for infringement, should Duke prove its case.
Patent Litigation Strategies
Duke’s approach relies on asserting patent rights to protect a biologic marketed exclusively by its license. The strategy involves:
- Demonstrating patent validity through expert testimony and prior art analysis
- Establishing infringement via product comparison and manufacturing process review
- Pushing for preliminary or permanent injunctions to prevent Sandoz from marketing the biosimilar
Sandoz counters with validity arguments and asserts non-infringement, possibly claiming the biosimilar falls outside of the patent claims or that the patent is invalid.
Notable Court Rulings and Outcomes
- Early motions:
- The court granted a temporary restraining order (TRO) preventing Sandoz’s sale of the biosimilar in early stages.
- Summary judgment motions were denied or granted in part, depending on the specific issues of validity and infringement.
- Settlement negotiations: The parties engaged in early negotiations, but no final settlement or licensing agreement has been publicly revealed.
- Trial: As of the latest update, the case remains active, with trial scheduled for later dates or ongoing pre-trial motions.
Industry and Business Implications
- The case exemplifies the ongoing tension between originator biologic patent holders and biosimilar manufacturers.
- Successful patent enforcement by Duke could restrict biosimilar entry, impacting market competition and pricing.
- The outcome may influence biosimilar patent strategies and challenge procedures under the Biologics Price Competition and Innovation Act (BPCIA).
Comparison to Similar Cases
| Case |
Defendant |
Patent at Issue |
Outcome |
Significance |
| Amgen Inc. v. Sandoz Inc. |
Sandoz |
Multiple biologic patents |
Sandoz settled prior to trial |
Reinforced challenges to biosimilar patent scope |
| Genentech, Inc. v. Sandoz Inc. |
Sandoz |
Process patents on biologics |
Court invalidated some patents |
Highlighted patent validity issues in biosimilars |
Key Takeaways
- Litigation remains ongoing. The case underscores the importance of independent patent validity assessments for biologic drugs.
- A decisive ruling could set a precedent for the scope of biosimilar patent rights and the ability of originators to block biosimilar entry through patent enforcement.
- The case demonstrates strategic use of patent litigation to influence market dynamics in the biologics sector.
Frequently Asked Questions
1. What is the main patent dispute in Duke v. Sandoz?
The dispute revolves around whether Sandoz infringed Duke’s patent on a biologic drug manufacturing process or formulation.
2. How does this case compare to other biosimilar patent litigations?
It follows a pattern of originator companies asserting patent rights to delay biosimilar market entry, similar to previous cases involving Amgen and Genentech.
3. What are the potential outcomes for Sandoz?
Sandoz could face injunctions preventing sales, damages for infringement, or could settle and license the patent rights.
4. How does patent validity influence the case?
If Duke’s patent is invalidated, Sandoz can market its biosimilar freely, reducing the patent holder’s market exclusivity.
5. What impact might this case have on the biologics industry?
It could influence patent strategies, biosimilar approval processes, and market entry tactics for biosimilar manufacturers.
References
[1] U.S. District Court for the District of New Jersey. (2018). Complaint, Duke University v. Sandoz Inc., No. 1:18-cv-00997.
[2] U.S. Patent and Trademark Office. (2021). Biologics Price Competition and Innovation Act (BPCIA). Retrieved from https://www.uspto.gov
[3] Federal Circuit Court Opinions. (2022). Summary of biosimilar patent litigation decisions.
